Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia

$300,000R01FY2006FDFDA

Point Therapeutics, Inc., Boston MA

Investigators

Margaret J Uprichardcontact

View original record on NIH RePORTER →

Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia · GrantIndex